Product Information
BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET is a generic product labeled by PAI Holdings LLC, priced at $0.6628 per EA under NDC 00121203630. Its NADAC has been published 135 times since Mar 6, 2024.
FDA first approved this application on Oct 16, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET
buprenorphine hydrochloride and naloxone hydrochlorideStrength
8; 2 mg/1; mg/1
Manufacturer
PAI Holdings LLCNDC
00121203630
Classification
Generic
Dosage Form
TABLET
Route
SUBLINGUAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA204431FDA Approved
10/16/2015
TE Code
AB
On Market Since
9/5/2023
Pharmacological Classes
Price Statistics
The NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has been published 135 times since Mar 6, 2024, and over the history we have for it it has declined 34.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6628 per EA |
|---|---|
| All-time high | $1.0433 (Apr 10, 2024) |
| All-time low | $0.6322 (Jul 22, 2026) |
| 52-week high | $0.7191 |
| 52-week low | $0.6322 |
| Median price | $0.7191 |
| Average price | $0.7451 |
| Largest weekly change | +29.6% (Aug 21, 2024) |
| Weeks tracked | 135 |
| Tracking since | Mar 6, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the buprenorphine hydrochloride and naloxone hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
PAI Holdings LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
buprenorphine hydrochloride and naloxone hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET, manufactured by PAI Holdings LLC, is $0.6628 per EA (NDC 00121203630), effective Sep 30, 2026.
How has the price of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET changed over time?
Over the history we have for it, the NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has declined 34.1%. It has been tracked across 135 weekly CMS publications since Mar 6, 2024.
What are the highest and lowest recorded NADAC prices for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?
Since Mar 6, 2024, the NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has ranged from a low of $0.6322 (Jul 22, 2026) to a high of $1.0433 (Apr 10, 2024), with a median of $0.7191 per EA.
Are there cheaper alternatives to BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?
No other NADAC-published product currently shares the active ingredient and strength of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?
BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET (NDC 00121203630) is labeled by PAI Holdings LLC, and CMS classifies it as a generic product.